{
  "report_rows": [
    {
      "kpi": "Adjusted EPS (Q1 FY27)",
      "prediction": "BEAT",
      "answer": "pred ~$9.60 vs. cons $9.46",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Total Revenue (Q1 FY27)",
      "prediction": "MISS",
      "answer": "pred ~$102.8B vs. cons $104.25B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "North America Pharmaceutical segment revenue growth (y/y)",
      "prediction": "MISS",
      "answer": "pred ~4.0% vs. cons/guide-midpoint ~6.0%",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY2027 Adjusted EPS guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~$44.20 midpoint vs. cons ~$44.05 (FY2027)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2027 Consolidated revenue growth guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~7.0% (5-9% range midpoint) vs. cons 6.6% (FY2027)",
      "confidence": "LOW"
    },
    {
      "kpi": "FY2027 Adjusted operating profit growth guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~10.0% (8-12% range midpoint) vs. cons ~9.5% (FY2027)",
      "confidence": "LOW"
    },
    {
      "kpi": "FY2027 Free cash flow guidance",
      "prediction": "LOWER",
      "answer": "guide ~$4.7B (4.5-4.9B range) vs. cons ~$4.9B (FY2027)",
      "confidence": "LOW"
    },
    {
      "kpi": "MMS separation/IPO timeline commentary",
      "prediction": "UNCHANGED",
      "answer": "guide ~2H CY2027 IPO target vs. cons 2H CY2027 expectation (FY2027-CY2027)",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": -3.0,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": -5.0,
  "day5_path": "FADE",
  "day5_rationale": "Even with a modest headline EPS beat, a revenue miss driven by branded-pricing/IRA headwinds and softer GLP-1 sequential trends in the largest segment (NA Pharmaceutical) implies downward pressure on out-quarter revenue and margin models; with FY27 guidance merely reaffirmed (not raised) against a stock priced near all-time highs on a rich relative multiple, sell-side is likely to trim FY27/FY28 revenue and FCF estimates even as EPS holds, producing continued multiple compression over the following days as the 'quality of beat' concern outweighs the EPS headline.",
  "day5_confidence": "MEDIUM"
}